Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 analysis of a phase 1/2 study

JAMA Oncology

Volumn 4, Issue 8, 2018, Pages 1106-1110

  Fathi, Amir T ^a   DiNardo, Courtney D ^b   Kline, Irina ^c   Kenvin, Laurie ^c   Gupta, Ira ^c   Attar, Eyal C ^d   Stein, Eytan M ^e   De Botton, Stephane ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CELGENE CORPORATION   (United States)

^d AGIOS PHARMACEUTICALS   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ENASIDENIB; ISOCITRATE DEHYDROGENASE 2; AG-221; AMINOPYRIDINE DERIVATIVE; ENZYME INHIBITOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TRIAZINE DERIVATIVE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ENZYME DEFECT; FEMALE; FEVER; HUMAN; HYPOXIA; ISOCITRATE DEHYDROGENASE DIFFERENTIATION SYNDROME; LEUKOCYTOSIS; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RETROSPECTIVE STUDY; ADVERSE EVENT; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FOLLOW UP; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROGNOSIS; SYNDROME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINOPYRIDINES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SYNDROME; TRIAZINES;

EID: 85049159248     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.4695     Document Type: Article

References (16)

1. Korn C, Méndez-Ferrer S. Myeloid malignancies and microenvironment. Blood. 2017;129(7):811-822.
2. Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20):4205-4214.
3. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731.
4. Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr J Hematol Infect Dis. 2011;3(1):e2011059.
5. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95(1):90-95.
6. Losman JA,Kaelin WG Jr.Whatadifference ahydroxylmakes:mutantIDH,(R)-2-hydroxyglutarate, andcancer.GenesDev.2013;27(8):836-852.
7. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
8. Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7(5):478-493.
9. Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732-741.
10. Birendra KC, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016;16(8):460-465.
11. Medical Dictionary for Regulatory Activities. https://www.meddra.org/. Accessed November 8, 2017.
12. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053
13. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published correction in J Clin Oncol. 2004;22(3):576]. J Clin Oncol. 2003;21(24): 4642-4649.
14. National Institutes of Health and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), v4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14 _QuickReference_5x7.pdf. Updated June 14, 2010. Accessed November 17, 2017.
15. Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000;18(13): 2620-2625.
16. Fan B, Chen Y, Wang F, et al. Pharmacokinetic/ pharmacodynamic (PK/PD) evaluation of AG-221, a potent mutant IDH2 inhibitor, from a phase 1 trial of patients with IDH2 mutation-positive hematologic malignancies [abstract 379]. Haematologica. 2015; 100(suppl 1):379.